N E W S B Y T E S
USV partners Biogenomics to launch INSUQUICK , the first biosimilar Insulin Aspart for people with diabetes in India
USV and Biogenomics have launched INSUQUICK ®, India ’ s first biosimilar Insulin Aspart , which will improve access for people with diabetes . InsuQuick is a “ Make in India ” product , developed and manufactured using 100 % indigenous technology , and has undergone a robust clinical program to ensure global quality standards . It is available in all metros , and Tier I / II cities . Insuquick will be available in cartridges , vials , and prefilled disposable pens , offering flexibility tailored to the needs of people with diabetes . The disposable and reusable pens are contemporary and lightweight in design and have a legible scale and audible clicks for precise incremental settings .
Prashant Tewari , Managing Director , USV Private Limited , said , “ As a leader in the oral anti-diabetes segment , our entry into injectables is a strategic step towards bolstering our market presence and our aspiration to lead in the diabetes market . We have collaborated with Biogenomics to provide globalquality insulin aspart for our people with diabetes .”
Lupin and Amman Pharma sign exclusive licensing & supply agreement for Ranibizumab Biosimilar
Lupin Limited has partnered with Amman Pharmaceuticals for exclusive marketing and commercialization of Ranibizumab , a biosimilar of Lucentis ®, in the Middle East region , including select territories of Jordan , Saudi Arabia , UAE , Iraq , Lebanon , and other GCC countries . Both Lupin and Amman Pharma are united in their mission to provide innovative , high-quality healthcare solutions to patients in the MENA region . Ranibizumab is a recombinant humanized IgG1 monoclonal antibody fragment that binds to and inhibits vascular endothelial growth factor
48
BioVoiceNews | January / February 2024